AP1896A - The method of treating cancer - Google Patents

The method of treating cancer

Info

Publication number
AP1896A
AP1896A APAP/P/2004/003070A AP2004003070A AP1896A AP 1896 A AP1896 A AP 1896A AP 2004003070 A AP2004003070 A AP 2004003070A AP 1896 A AP1896 A AP 1896A
Authority
AP
ARIPO
Prior art keywords
cancer
treating cancer
mycobactcrium
management
useful
Prior art date
Application number
APAP/P/2004/003070A
Other languages
English (en)
Other versions
AP2004003070A0 (en
Inventor
Bakulesh Mafatlal Khamar
Original Assignee
Bakulesh Mafatlal Khamar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bakulesh Mafatlal Khamar filed Critical Bakulesh Mafatlal Khamar
Publication of AP2004003070A0 publication Critical patent/AP2004003070A0/xx
Application granted granted Critical
Publication of AP1896A publication Critical patent/AP1896A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
APAP/P/2004/003070A 2001-12-10 2002-12-10 The method of treating cancer AP1896A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1167MU2001 2001-12-10
PCT/IB2002/005516 WO2003049667A2 (en) 2001-12-10 2002-12-10 The method of treating cancer

Publications (2)

Publication Number Publication Date
AP2004003070A0 AP2004003070A0 (en) 2004-06-30
AP1896A true AP1896A (en) 2008-10-08

Family

ID=11097334

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/003070A AP1896A (en) 2001-12-10 2002-12-10 The method of treating cancer

Country Status (9)

Country Link
US (1) US7972609B2 (https=)
JP (1) JP4527979B2 (https=)
AP (1) AP1896A (https=)
AU (1) AU2002348738B2 (https=)
CA (1) CA2469266C (https=)
GB (1) GB2389532C (https=)
NZ (1) NZ533417A (https=)
UA (1) UA79952C2 (https=)
WO (1) WO2003049667A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048434B2 (en) * 2005-04-25 2011-11-01 Cadila Pharmaceuticals, Ltd. Vaccine adjuvants
EA023046B1 (ru) * 2006-11-23 2016-04-29 Кадила Фармасьютикалз Лимитед Применение инактивированной нагреванием micobacterium w для снижения индуцированной tlr активности
US20100104536A1 (en) * 2007-03-20 2010-04-29 Indravadan Ambalal Modi P38 inhibitors
RU2010101164A (ru) * 2007-06-28 2011-08-10 Кадила Фармасьютикалз Лтд. (In) Модулятор митоген-активируемой протеинкиназы
WO2011083493A1 (en) * 2010-01-08 2011-07-14 National Institute Of Immunology Human chorionic gonadotropin (hcg) based vaccine for prevention and treatment of cancer
JP2013519723A (ja) * 2010-02-19 2013-05-30 カディラ ファーマシューティカルズ リミテッド 実質的に保持された免疫原性を有する死細胞の薬学的組成物
CN105943559A (zh) * 2010-10-13 2016-09-21 特莱斯塔治疗知识产权公司 细菌核糖核酸细胞壁组合物及其制备和使用方法
CN103338779B (zh) * 2011-01-11 2015-12-23 卡帝拉药物有限公司 分枝杆菌w在制备治疗癌症药物中的用途
TR201101874A2 (tr) * 2011-02-25 2011-08-22 Leyla A�An Nac�Ye Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri.
RU2615346C2 (ru) * 2011-02-28 2017-04-04 Кадила Фармасьютикалз Лимитед Терапевтическая вакцина против рака
ES2647768T3 (es) * 2011-07-05 2017-12-26 Cadila Pharmaceuticals Limited Antígeno de cáncer
US20200368293A1 (en) * 2018-01-18 2020-11-26 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869645A (en) * 1997-10-15 1999-02-09 Board Of Trustees Of The University Of Illinois Method for isolating high molecular weight antineoplastic glycans using urea
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5767156A (en) * 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
KR20050008453A (ko) * 2002-03-08 2005-01-21 바쿠레시 마파탈 카마르 결핵 관리에 유용한 약제학적 조성물의 제조방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
US5869645A (en) * 1997-10-15 1999-02-09 Board Of Trustees Of The University Of Illinois Method for isolating high molecular weight antineoplastic glycans using urea

Also Published As

Publication number Publication date
AU2002348738B2 (en) 2007-11-08
JP4527979B2 (ja) 2010-08-18
US20070259005A1 (en) 2007-11-08
UA79952C2 (en) 2007-08-10
JP2005528332A (ja) 2005-09-22
CA2469266A1 (en) 2003-06-19
GB2389532B (en) 2004-10-27
WO2003049667A2 (en) 2003-06-19
AP2004003070A0 (en) 2004-06-30
AU2002348738A1 (en) 2003-06-23
WO2003049667A3 (en) 2003-10-09
US7972609B2 (en) 2011-07-05
GB2389532A (en) 2003-12-17
CA2469266C (en) 2014-02-11
GB2389532C (en) 2005-09-08
GB0322773D0 (en) 2003-10-29
NZ533417A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
PL312219A1 (en) Application of nona- and decapeptides in obtaining a therapeutic agent for fighting against aids
IL159257A0 (en) Substituted oxazolidinones for combinational therapy
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
BG105534A (en) 5ht1 means and method for the treatment of migraine
WO2004019884A3 (en) Agents and methods for enhancing bone formation
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
BR9811780A (pt) Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
AP1896A (en) The method of treating cancer
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
NZ507203A (en) Use of dexmedetomidine for ICU sedation
GB0020504D0 (en) Therapeutic method
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
TNSN04235A1 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
PT1076561E (pt) Terapia de combinacao para o tratamento de tumores
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
MD980129A (en) Antiherpetic remedy
IL129267A0 (en) Treatment of urinary incontinence and compositions for use therein